Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery

November 15, 2026 updated by: Ain Shams University

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

  1. Pre-operative settings:

    Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).

    Patients will be divided into two groups:

    Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.

    Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.

  2. Intraoperative Settings:

All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.

ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.

Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.

Intra-operative bradycardia (pulse rate <50) will be treated with atropine 0.6 mg.

Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.

Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.

Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.

Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.

Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.

  1. Hemodynamic monitoring:

    Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.

  2. Assessment of post-operative pain & sedation:

By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Hala said Hassan, MD
  • Phone Number: +201147784179

Study Locations

    • Abbassia, Egypt
      • Cairo, Abbassia, Egypt, Egypt
        • Recruiting
        • Ain Shams University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients aged from 21-60 years.
  • Patients ASA I or II undergoing elective Robot-Assisted gynecological surgery under general anesthesia.

Exclusion Criteria:

  • Patient refusal.
  • ASA III and ASA IV.
  • A known history of allergy to the drugs used.
  • Patients on chronic steroid therapy.
  • Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group D (Dexmedetomidine)

Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery.

IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end.

Placebo Comparator: Group P (Placebo)

Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion).

Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Cortisol Level
Time Frame: Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels.

Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Rescue Analgesia
Time Frame: Up to 24 hours postoperatively

The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain

  • 1-3: Mild pain
  • 4-6: Moderate pain
  • 7-10: Severe pain
Up to 24 hours postoperatively
Serum Glucose level
Time Frame: Serum glucose: Baseline, just after incision, and 6 hours post-induction.

Blood serum level of glucose to assess metabolic stress.

Serum glucose: Baseline, just after incision, and 6 hours post-induction.
Numerical Pain Distress Scale (NPDS) Score
Time Frame: Upon recovery in PACU and throughout the first 24 hours postoperatively.

Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain).

Higher number means high pain intensity.

Upon recovery in PACU and throughout the first 24 hours postoperatively.
Ramsay Sedation Scale Score
Time Frame: Upon recovery in PACU and during the first 2 hours postoperatively.

Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus).

Upon recovery in PACU and during the first 2 hours postoperatively.
Intraoperative Analgesic Consumption
Time Frame: Intraoperatively measured from induction till end of surgery.

Total intraoperative fentanyl consumption.

Intraoperatively measured from induction till end of surgery.
Intraoperative Mean Arterial Pressure (MAP)
Time Frame: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
Incidence of Side Effects and Complications
Time Frame: Up to 24 hours postoperatively.

Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression.

It will be recorded as yes or No .

Up to 24 hours postoperatively.
Lactate Level
Time Frame: Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.

Blood serum lactate level to assess metabolic stress.

Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
Postoperative Analgesic Consumption
Time Frame: through 24 hours postoperatively.

Total postoperative meperidine consumption.

through 24 hours postoperatively.
Intraoperative Anesthetic Consumption
Time Frame: Intraoperatively measured from induction till end of surgery.

Total intraoperative consumption of isoflurane and average end-tidal concentration

Intraoperatively measured from induction till end of surgery.
Intraoperative Heart Rate (HR)
Time Frame: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

September 13, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FMASU MD328/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.